Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine

Chemotherapy for multiple primary cancers is challenging. We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. A 78-year-old woman with advanced EGFR-mutated lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Akiyama, Norimichi, Karayama, Masato, Iwaizumi, Moriya, Kusama, Yukiko, Kono, Masato, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Inui, Naoki, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635316/
https://www.ncbi.nlm.nih.gov/pubmed/28794362
http://dx.doi.org/10.2169/internalmedicine.8312-16

Ejemplares similares

Ejemplares similares